Clinical trials: Phyllodes Tumor
Radiotherapy, Adjuvant, Phyllodes Breast Tumor
Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection
Breast phyllodes tumors (PT) are rare fibroepithelial neoplasms originating from stromal tissue and account for less than 1% of all breast tumors.
- Conditions
- Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis
- Trial name
- NCT06780059
- Testing
- Adjuvant Radiotherapy, R0 resection
- Where
- 3 sites in China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phyllodes Breast Tumor, Artificial Intelligence
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border…
- Conditions
- Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
- Trial name
- NCT06286267
- Testing
- imaging
- Where
- 4 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Phyllodes Breast Tumor, Prognosis
Breast Phyllodes Tumors: Based on 20-year Real-world Data From China
Phyllodes tumor (PT) is a rare type of breast tumor made up of both connective tissue (stroma) and gland tissue (epithelium). It accounts for less than 1% of all breast tumors. The main symptom is a fast-growing, painless lump.
- Trial name
- NCT07636096
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University